NEW BRUNSWICK, N.J., March 12 /PRNewswire/ -- Johnson & Johnson today announced that it has received separate subpoenas from the U.S. Attorney's Office in Philadelphia, the U.S. Attorney's Office in Boston and the U.S. Attorney's Office in San Francisco. The subpoenas relate to investigations by those three offices previously disclosed in SEC filings and directed, respectively, to sales and marketing of RISPERDAL by Janssen, TOPAMAX by Ortho-McNeil and NATRECOR by Scios -- each subsidiaries of Johnson & Johnson.
The subpoenas request information regarding Johnson & Johnson's corporate supervision and oversight of these three subsidiaries, including their sales and marketing of these drugs.
Johnson & Johnson will cooperate in responding to these requests.
Johnson & JohnsonCONTACT: Jeffrey J. Leebaw, +1-732-524-3350, or Bill Price,+1-732-524-6623, both Media Contacts; Louise Mehrotra, +1-732-524-6491, orStan Panasewicz, +1-732-524-2524, or Lesley Fishman, +1-732-524-3922, allInvestor Contacts
Web site: http://www.jnj.com//
Company News On-Call: http://www.prnewswire.com/comp/467347.html/
